Immunogenicity of the ChAdOx1 nCoV-19 vaccine in patients with hematologic malignancies.
Chayapa ThookhammeManassamon NavinpipatAimwipa SasakulPakthipa PattarakosolKamoltip LertchaisatapornKriangkrai TawinpraiPannee PraditsuktavornPublished in: Clinical and experimental vaccine research (2023)
Immune responses were impaired in individuals with hematologic malignancies, particularly patients undergoing ongoing therapy and B-cell-depleting therapy. Additional vaccinations should be considered for these patients, and further investigated.